Understanding RPE Cell Differences to Treat Age-Related Macular Degeneration
Targeting lysosome/RPE heterogeneity in AMD pathobiology as a novel therapy
This project explores how different types of cells in the eye contribute to early age-related macular degeneration (AMD) to find new ways to help people with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11231558 on NIH RePORTER |
What this research studies
Age-related macular degeneration (AMD) causes vision loss, and currently, there are no treatments for its early stages. This work focuses on special cells in the eye called RPE cells, which are known to degenerate in AMD. We are looking closely at how these RPE cells are not all the same and how some of them might change in a way that makes them resistant to dying, potentially driving the disease for a long time. By understanding these differences and how problems with cell waste removal (lysosomal clearance) might start these changes, we hope to uncover new targets for treatment. Our goal is to develop new therapies that can stop or slow down early AMD.
Who could benefit from this research
Good fit: This foundational work is for anyone interested in the underlying causes of age-related macular degeneration, particularly those with early forms of the disease.
Not a fit: Patients with advanced forms of AMD that already have established treatments may not directly benefit from this early-stage research.
Why it matters
Potential benefit: If successful, this work could lead to the first effective treatments or preventions for early age-related macular degeneration, preserving vision for many people.
How similar studies have performed: This approach is described as a departure from previous norms, suggesting it is a novel and untested strategy for understanding AMD.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Sinha, Debasish — Johns Hopkins University
- Study coordinator: Sinha, Debasish
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.